Short-Term Pioglitazone Treatment Improves Vascular Function Irrespective of Metabolic Changes in Patients With Type 2 Diabetes

Martens FM, Visseren FL, de Koning EJ, Rabelink TJ 

To determine whether pioglitazone influences endothelial function directly, we examined in a randomized, crossover, placebo-controlled, double-blind trial the effects of 4 weeks of pioglitazone treatment in 20 male type 2 diabetic patients. We conclude that short-term pioglitazone treatment ameliorates endothelial dysfunction in conduit arteries irrespective of significant beneficial changes in plasma levels of insulin, FFA, adiponectin, or CRP in type 2 patients with diabetes.  

 

 


Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-Term Pioglitazone Treatment Improves Vascular Function Irrespective of Metabolic Changes in Patients With Type 2 Diabetes. J Cardiovasc Pharmacol. 2005;46:773-778. 

Last Modified: 2/26/2013